in vivo Evaluation of a Tissue Blood Vessel

描述(由申请人提供)： 在工业化世界，冠心病是主要的死亡原因。尽管基于导管的介入技术取得了进展，但搭桥术仍然是长期疗效最好的治疗方法。这种方法的主要限制是本地血管的可用性。研究人员已经研究了合成移植物、细胞种子合成材料和脱细胞组织作为天然移植物的替代品。这些可供选择的血管管道受到早期血栓和/或动脉瘤的限制。我们已经开发出一种完全自体的人类组织工程血管(TEBV)，它具有功能内皮和20倍生理血压的破裂压力。由于血管是完全自体的，我们预计不会发生免疫反应和随后的降解。我们已经完成了制造这些TEBV的关键步骤自动化的第一阶段目标，我们已经从生物力学角度表征了从患有晚期血管疾病的人类细胞中构建的TEBV。我们已经将这些人类血管移植到犬和大鼠体内(分别开放14天和90天)，以成功地展示短期机械强度和抗血栓形成能力。在第二阶段，我们会： 。在动物模型中评估疗效，优化人类TEBV的依从性和强度。研究扩散和优化单位厚度强度 。集成生物反应器模块

DESCRIPTION (provided by applicant): Coronary heart disease is the leading cause of death in the industrialized world. Despite advances in catheter-based interventions, bypass remains the treatment with the greatest long-term efficacy. The primary limitation of this approach is the availability of native vessels. Researchers have investigated synthetic grafts, cell seeded synthetics, and decellularized tissues as alternates to native grafts. These alternative vascular conduits are limited by early thrombosis and/or aneurysm. We have developed a completely autologous human tissue engineered blood vessel (TEBV) with a functional endothelium and burst pressures 20-fold physiological blood pressure. Since the vessel is completely autologous, we do not expect immune reaction and subsequent degradation. We have completed our Phase I objectives of automating key steps in the fabrication of these TEBVs and we have biomechanically characterized TEBVs built from cells harvested from humans with advanced vascular disease. We have xenografted these human vessels into canines and rats (14 and 90 day patency respectively) to successfully demonstrate short-term mechanical strength and anti-thrombogenicity. In Phase II, we will: . Evaluate efficacy in an animal model,Optimize compliance and strength of the human TEBVs, . Study diffusion and optimize strength per unit thickness . Integrate the bioreactor modules